Rapamycin is used frequently in both transplantation and oncology. Although historically
thought to have little diabetogenic effect, there is growing evidence of β-cell toxicity. This …

A substantial proportion of the transplanted islet mass fails to engraft due to death by
apoptosis, and a number of strategies have been explored to inhibit β-cell loss. Inhibition of …

Background Islet transplantation offers the potential to improve glycemic control in a
subgroup of patients with type 1 diabetes mellitus who are disabled by refractory …

Transplantation of pancreatic islets is a promising strategy to alleviate the unstable blood‐
glucose control that some patients with diabetes type 1 exhibit and has seen many …

Islet transplantation is a feasible therapeutic alternative for metabolically labile patients with
type 1 diabetes. The primary therapeutic target is stable glycemic control and prevention of …

A major challenge for human allogeneic islet transplantation is the development of effective
methods to induce donor-specific tolerance to obviate the need for life-long …

Developing a device that protects xenogeneic islets to allow treatment and potentially cure
of diabetes in large mammals has been a major challenge in the past decade. Using …

Successful islet transplantation depends on the infusion of sufficiently large quantities of
islets, but only a fraction of transplanted islets can survive and become engrafted, and yet …

The encapsulation of therapeutic cells permits the implantation of allogeneic and
xenogeneic cells for the regulation of certain physiological processes damaged by the death …

The bioartificial pancreas (BAP) represents a viable solution for the treatment of type 1
diabetes (T1D). By encapsulating pancreatic cells in a semipermeable membrane to allow …